News
Sartar Therapeutics investment round was a success
Sartar’s investment round closed ahead of time on Monday (19.10.2020). We achieved incredible outcome of 2 300 000 euros just in six days. Sartar wishes to thank all investors for taking part in the round. We would also like to thank Springvest, for helping us to achieve this goal. Thank you!
Sartar was chosen among the top 30 innovative life science companies in RESI Innovation Challenge
We are honored to be selected as one of the most innovative companies in RESI Europe 2020 Innovation Challenge in the therapeutics category. Link to original news
Sartar was granted a Japan patent
Sartar was awarded a patent in Japan for the use of anagrelide in cancer therapy.
Pekka Simula joins Sartar’s board of directors
Sartar strengthens the board of directors. CEO of Herantis Pharma, Pekka Simula, has been appointed as a new member to the Sartar Therapeutics board of directors.
Sartar was awarded a U.S. patent
Sartar was awarded a U.S. patent for use of anagrelide in cancer therapy.